At-home testing kit company myLab Box has expanded its services with the addition of six new tests for sexually transmitted diseases, bringing the company’s total offerings to 10 tests sold in the United States.
The company launched the new tests in response to increasing rates of STDs in the country, along with the uncertain future of healthcare services under a new administration. The new tests cover Hepatitis C, Herpes Simplex 2, HPV, Mycoplasma, Syphillis and Ureapaslma, available to both men and women. They can be purchased on the company’s website or on most major ecommerce sites like Amazon or Walmart, and can be bought individually or as a combination kit.
“myLAB Box was created in large part due to the unstable healthcare climate in the US and what we saw as the need for alternatives to payer-based health systems,” Lora Ivanova, co-founder and chief medical officer of myLAB Box, said in a statement.
The company’s mantra is “Don’t stress, just test,” and its mission is to increasing testing rates by making it easy, affordable and discreet. Users order the tests online, then collect their sample of either urine, a small blood prick sample or swab, (depending on the test), place it in the provided containers and mail it back in the self-addressed envelope to myLab Box’s certified lab partners. Results are available within days and accessible online with a simple dashboard. Those with positive results are offered complimentary telemedicine consultations with licensed physicians.
The service is similar to that of EverlyWell, which just launched its suite of STD tests. myLab Box's prices range from $189 (for a 4-test panel) to $399 for the full, 10-test panel versus EverlyWell’s 7-panel test for $249, and both are covered by HSA or FSA accounts. It has advantages that Planned Parentood or STD Check.com don’t have, like nationwide availability, an easy-to-read results dashboard, or sharing options.
“From affordable screening to complimentary physician consultations for positives, every aspect of the myLAB Box service is designed to be something a user can easily handle out-of-pocket and without complications,” said Ivanova. “The recent shake-up of our healthcare systems further deepens our resolve to grow our offering and develop a new hassle-free lab testing model. We believe this is not just great business, but a much needed resource to curb a widespread epidemic in the US today.”